![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Thursday, April 28, 2016 2:39:36 PM
However good business planning and investor support would benefit from confirming any FDA status change that would help to move the FDA process forward.
IE: Why did company allocate marketing expense to PR's regarding NHS....
Would seem irrational to PR NHS progress and not PR FDA progress.
Especially since we are talking about publicly available information.
http://www.bielcorp.com/bioelectronics-and-b-braun-medical-ltd-apply-for-prescription-payment-clearance-on-the-uk-drug-tariff/
-->FREDERICK, MD. Feb 18, 2016 — BioElectronics Corporation (OTC Pink: BIEL), the maker of advanced consumer medical devices, announced today that B. Braun has initiated the application for a listing of RecoveryRx® on the National Health Service (NHS) drug tariff (http://www.nhsbsa.nhs.uk/PrescriptionServices/4940.aspx).The UK drug tariff list establishes payment for prescription costs in the UK.....<--
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM